169 related articles for article (PubMed ID: 23274396)
41. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Van der Speeten K; Stuart OA; Chang D; Mahteme H; Sugarbaker PH
Cancer Chemother Pharmacol; 2011 Jul; 68(1):147-56. PubMed ID: 20857115
[TBL] [Abstract][Full Text] [Related]
42. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
[TBL] [Abstract][Full Text] [Related]
43. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
Yan TD; Morris DL
Ann Surg; 2008 Nov; 248(5):829-35. PubMed ID: 18948811
[TBL] [Abstract][Full Text] [Related]
44. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis.
Nesher E; Greenberg R; Avital S; Skornick Y; Schneebaum S
Isr Med Assoc J; 2007 Nov; 9(11):787-90. PubMed ID: 18085034
[TBL] [Abstract][Full Text] [Related]
45. Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin.
Mahteme H; Sugarbaker PH
Br J Surg; 2004 Sep; 91(9):1168-73. PubMed ID: 15449269
[TBL] [Abstract][Full Text] [Related]
46. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
Verschraegen CF; Kumagai S; Davidson R; Feig B; Mansfield P; Lee SJ; Maclean DS; Hu W; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Oct; 129(10):549-55. PubMed ID: 14513369
[TBL] [Abstract][Full Text] [Related]
47. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
Rossi CR; Foletto M; Mocellin S; Pilati P; De SM; Deraco M; Cavaliere F; Palatini P; Guasti F; Scalerta R; Lise M
Cancer; 2002 Jan; 94(2):492-9. PubMed ID: 11900234
[TBL] [Abstract][Full Text] [Related]
48. Factors influencing early postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Arakelian E; Gunningberg L; Larsson J; Norlén K; Mahteme H
Eur J Surg Oncol; 2011 Oct; 37(10):897-903. PubMed ID: 21783337
[TBL] [Abstract][Full Text] [Related]
49. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Chua TC; Morris DL; Esquivel J
Ann Surg Oncol; 2010 May; 17(5):1330-6. PubMed ID: 20033321
[TBL] [Abstract][Full Text] [Related]
50. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
51. Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.
Asero S; Caruso M; Vallone N; Luciani AG; Lombardo V; Terranova G; Ettore G; Giannone G
In Vivo; 2009; 23(4):645-7. PubMed ID: 19567402
[TBL] [Abstract][Full Text] [Related]
52. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
Elias D; Raynard B; Boige V; Laplanche A; Estphan G; Malka D; Pocard M
J Surg Oncol; 2005 Jun; 90(4):220-5. PubMed ID: 15906364
[TBL] [Abstract][Full Text] [Related]
53. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
Zeamari S; Floot B; van der Vange N; Stewart FA
Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
[TBL] [Abstract][Full Text] [Related]
55. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival.
Hagendoorn J; van Lammeren G; Boerma D; van der Beek E; Wiezer MJ; van Ramshorst B
Eur J Surg Oncol; 2009 Aug; 35(8):833-7. PubMed ID: 19019619
[TBL] [Abstract][Full Text] [Related]
56. [Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Roviello F; Caruso S; Marrelli D; Pedrazzani C; Neri A; De Stefano A; Pinto E
G Chir; 2011 Apr; 32(4):211-33. PubMed ID: 21554854
[TBL] [Abstract][Full Text] [Related]
57. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
Omohwo C; Nieroda CA; Studeman KD; Thieme H; Kostuik P; Ross AS; Holter DR; Gushchin V; Merriman B; Sardi A
J Am Coll Surg; 2009 Sep; 209(3):308-12. PubMed ID: 19717034
[TBL] [Abstract][Full Text] [Related]
58. [Intraperitoneal chemotherapy with oxaliplatin after complete cytoreduction for peritoneal carcinomatosis from colorectal carcinoma: preliminary experience].
Mura G; Framarini M; Milandri C; Rosetti P; Vagliasindi A; Solfrini G; Mazza P; Verdecchia GM
Suppl Tumori; 2005; 4(3):S111-2. PubMed ID: 16437938
[TBL] [Abstract][Full Text] [Related]
59. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin.
Glehen O; Cotte E; Schreiber V; Sayag-Beaujard AC; Vignal J; Gilly FN
Br J Surg; 2004 Jun; 91(6):747-54. PubMed ID: 15164446
[TBL] [Abstract][Full Text] [Related]
60. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
